Analysis showing orphan drug list prices significantly higher in the U.S. than in the E.U. prompts questions about future pricing considerations for gene therapies

An analysis of orphan drug prices in the US raises concerns over the sustainability of gene therapy costs. This article explores factors influencing US drug prices , the potential impact of new EU pharmaceutical legislation and how pressure to curb spiralling drug prices is falling on US policy makers.